Interventional, open-label study of 18 mg Selincro(R) as needed use, in the treatment of patients with alcohol dependence in primary care

Trial Profile

Interventional, open-label study of 18 mg Selincro(R) as needed use, in the treatment of patients with alcohol dependence in primary care

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Alcohol withdrawal
  • Focus Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 29 Mar 2016 Status changed from completed to discontinued due to enrolment challenges as reported by ClinicalTrials.gov record.
    • 16 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Oct 2015 Planned End Date changed from 1 Apr 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top